Summary
The product EQ 500 mg (Boldenone Undecylenate), manufactured by Olympian Pharmaceutical, underwent independent testing to verify its authenticity and potency. The sample, identified by batch number 0069, was submitted by Olympian Pharmaceutical and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of Boldenone Undecylenate, with a concentration of 459.57 mg/ml, which is 8.09% below the labeled claim of 500 mg/ml.
The testing process began on 24 October 2024, with the sample received on 30 October 2024, and analysis completed on 01 November 2024. The results confirm the presence of the active ingredient, but the measured concentration is lower than the labeled amount. Independent third-party testing remains essential to validate these findings and ensure consistency across different batches. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Olympian Pharmaceutical
- Product Name: EQ 500 mg
- Active Ingredient: Boldenone Undecylenate
- Batch Number: 0069
- Expiration Date: Not provided
- Delivery Method: Injectable
Sample Acquisition and Testing
- Task Number: #51785
- Testing Ordered: 24 October 2024
- Sample Received: 30 October 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Olympian Pharmaceutical (Manufacturer)
- Analysis Paid For By: Olympian Pharmaceutical (Manufacturer)
Testing Results
- Specification: 500 mg/ml (as stated on the label)
- Measured Concentration: 459.57 mg/ml
- Accuracy: 91.91% (8.09% below the label claim)
Verification Details
Verification URL: https://janoshik.com/tests/51785_QW6CJ223VHSG
Evaluation of Manufacturer-Submitted Testing
This analysis confirms that EQ 500 mg is underdosed, with a measured concentration of 459.57 mg/ml, which is 8.09% below the labeled claim. While this deviation is noticeable, it remains within a moderate range. Since Olympian Pharmaceutical submitted and funded the test, independent validation through third-party testing remains crucial to confirm product uniformity across different batches. Further testing would enhance confidence in these findings and ensure consistent quality control.
Conclusion
The analysis confirms that EQ 500 mg is underdosed, with a measured concentration of 459.57 mg/ml, which is 8.09% below the labeled claim. While the presence of the active ingredient is verified, the lower concentration underscores the importance of continued testing to maintain high product standards. This report is provided as an educational and harm reduction resource, helping consumers make informed choices regarding steroid-based products.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may involve inherent biases; however, it provides useful data when critically assessed alongside third-party independent results. Readers are encouraged to use this information responsibly.
